Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163436
Status:
COMPLETED
Last Update Posted:
2016-11-30
First Post:
2005-09-12
Brief Title:
Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma 12 to 75 y BY9010M1-145
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Comparison of the Efficacy and Safety of 160 mcg Ciclesonide Administered Once Daily in the Evening With or Without Different Spacer Types in Patients With Asthma
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of the present study is to investigate the efficacy and safety of ciclesonide on lung function and safety Ciclesonide will be inhaled at one dose level once daily using an inhaler device with or without spacer The study duration consists of a baseline period 1 to 3 weeks and a treatment period 12 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None